Welcome to our dedicated page for Regenxbio news (Ticker: RGNX), a resource for investors and traders seeking the latest updates and insights on Regenxbio stock.
REGENXBIO Inc. reports news on its AAV gene therapy pipeline and manufacturing platform for rare, neuromuscular and retinal diseases. Recurring updates cover RGX-202 for Duchenne muscular dystrophy; clemidsogene lanparvovec (RGX-121) for MPS II; RGX-111 for MPS I; and surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy.
Company announcements also include FDA regulatory communications, clinical and preclinical data presentations, financial results, operational highlights, and collaboration activity with partners including Nippon Shinyaku and AbbVie. News on the NAV and NAVXpress platforms addresses AAV vector technology, product quality, and manufacturing capabilities used across REGENXBIO's investigational programs.
REGENXBIO (Nasdaq: RGNX) reported Q2 2026 revenues of $108.0 million, up sharply from $21.4 million a year earlier, driven mainly by a $100 million AbbVie milestone tied to first dosing in the Phase IIb/III NAAVIGATE diabetic retinopathy study. Net income was $22.7 million, or $0.43 per share, versus a $70.9 million loss in Q2 2025.
Cash, cash equivalents and marketable securities were $105.5 million on June 30, 2026; including July’s $100 million milestone and roughly $108 million in equity offering proceeds, pro forma cash exceeded $313 million, extending the cash runway into Q4 2027. Operationally, the Phase III AFFINITY DUCHENNE trial for RGX-202 met its primary endpoint with high statistical significance, RGX-202’s confirmatory study fully enrolled ahead of schedule, and the FDA confirmed no additional studies are needed for RGX-121’s planned Q3 2026 BLA resubmission. Topline data for surabgene lomparvovec (ABBV-RGX-314) wet AMD pivotal trials are expected in Q4 2026, with multiple BLA submissions targeted between 2026 and 2027.
REGENXBIO (Nasdaq: RGNX) will host a conference call on Thursday, August 6, at 8:00 a.m. ET to discuss financial results for the quarter ended June 30, 2026, and operational highlights. Webcast registration links are provided for listeners and analysts, with a replay available on the investor website about two hours after the call.
REGENXBIO (Nasdaq: RGNX) reported positive long-term data for investigational gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) at the ASRS 2026 meeting.
In wet AMD, Phase I/IIa Cohorts 3 and 4 receiving subretinal sura-vec at doses similar to those in ongoing ATMOSPHERE and ASCENT pivotal trials showed stable to improved visual acuity and meaningful reductions in anti-VEGF injection burden through five years, with no new safety signals and no intraocular inflammation in completers. An external control study indicated preserved vision, less retinal thickness fluctuation and significantly fewer injections versus real-world anti-VEGF therapy at one year.
In DR, 2.5-year follow-up from the ALTITUDE trial using suprachoroidal delivery at Dose Level 3 showed 55% of NPDR participants achieving >2-step DRSS improvement without additional treatment and 70% experiencing no vision-threatening events, with no intraocular inflammation in 17 participants. Topline wet AMD pivotal data with AbbVie from ATMOSPHERE and ASCENT are expected in Q4 2026.
REGENXBIO (Nasdaq: RGNX) priced an underwritten public offering of 10,003,889 common shares at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, before underwriting discounts and commissions. Expected gross proceeds are approximately $100 million, excluding the underwriters’ option.
The offering is expected to close on July 20, 2026, subject to customary conditions. REGENXBIO granted underwriters a 30-day option to buy up to an additional 1,667,250 common shares. Morgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are joint book-running managers.
REGENXBIO (Nasdaq: RGNX) announced that it intends to conduct an underwritten public offering of $100 million of its common stock, subject to market and other conditions. The company noted there is no assurance regarding completion, timing, actual size or final terms of the offering.
According to REGENXBIO, the company also plans to grant underwriters a 30-day option to purchase up to 15% additional common shares. Morgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint book-running managers. The offering will be made under an effective Form S-3 shelf registration statement filed in November 2025.
REGENXBIO (Nasdaq: RGNX) dosed the first patient in the Phase IIb/III NAAVIGATE trial of investigational surabgene lomparvovec in diabetic retinopathy using suprachoroidal delivery, triggering a $100 million milestone payment from AbbVie.
NAAVIGATE will evaluate a 1.0x1012 GC/eye dose in non-proliferative DR, with a primary endpoint of >2-step DRSS improvement at one year. The Phase IIb portion plans to enroll about 135 U.S. participants. REGENXBIO also plans to present long-term ALTITUDE and wet AMD data at ASRS 2026 and expects pivotal ATMOSPHERE and ASCENT topline data in Q4 2026.
REGENXBIO (Nasdaq: RGNX) completed dosing in the confirmatory study of RGX-202 for Duchenne muscular dystrophy, marking completion of the registrational development program.
This supports initiating a BLA in Q3 2026 under the accelerated approval pathway, targeting potential FDA approval in 2H 2027, backed by safety data from 63 patients and pivotal efficacy data from 30 patients.
REGENXBIO (Nasdaq:RGNX) announced agreement with the FDA on the path to resubmit its BLA for NAVSUNLI™, a potential one-time gene therapy for MPS II (Hunter syndrome). No additional studies or new patients are required, and the FDA plans an expedited review.
A Type A meeting is expected in July, with BLA resubmission targeted for Q3 2026.
REGENXBIO (Nasdaq: RGNX) will participate in two upcoming investor events: the 2026 RBC Capital Markets Global Healthcare Conference fireside chat on May 20, 2026 at 9:30 a.m. ET in New York, and the Stifel 2026 Virtual Ophthalmology Forum fireside chat on May 26, 2026 at 9:30 a.m. ET.
Live webcasts and 30-day replays will be available in the Investors section of REGENXBIO's website.
REGENXBIO (Nasdaq:RGNX) reported Q1 2026 results and key clinical milestones. Positive topline Phase III AFFINITY DUCHENNE® data for RGX-202 met its primary endpoint with high statistical significance, supporting a potential accelerated approval in 2027.
Q1 2026 revenue was $6.4M versus $89.0M a year ago, with a net loss of $90.1M. Cash and securities totaled $150.5M, expected to fund operations into early 2027. A $100M milestone from AbbVie is expected upon first patient dosing in the NAAVIGATE DR study in Q2 2026.